Morgan Stanley Upgrades Valeant Pharmaceuticals (VRX) to Overweight
VRX Hot Sheet
Rating Summary:6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Morgan Stanley upgraded Valeant Pharmaceuticals (NYSE: VRX) from Equal Weight to Overweight.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $49.03 yesterday, with a 52 week range of $32.05-$57.24.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $49.03 yesterday, with a 52 week range of $32.05-$57.24.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
- Deutsche Bank Upgrades Siemens (SI) to Buy; Subtle Shift
Create E-mail Alert Related Categories
UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
